Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

Summary

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and mechanisms of action. The moderate-to-severe pain space continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, significant unmet needs remain, as chronic pain subtypes-particularly neuropathic pain-do not respond well to existing therapies. This report assesses first-in-class innovation across the pain pipeline.

Scope

- There are 909 pipeline programs in active development for pain. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
- The market for pain treatment is heavily saturated. Which drug classes are used to treat pain? How do the drug classes in the market compare with those in the pipelines?
- Which molecular target classes are prominently represented in the first-in-class pain pipelines? Which first-in-class targets have been identified as most promising for the treatment of pain? Which first-in-class products have prior deal involvement?

Reasons to buy

- Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology for major pain subtypes.
- Visualize the composition of the pain market in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze and compare the pain pipeline and stratify by stage of development, molecule type, and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Recognize commercial opportunities by identifying first-in-class pipeline products for pain that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class pain products.